within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01M_QuinoloneAntibacterials.J01MA14_Moxifloxacin;

model Moxifloxacin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 5.444444444444445e-06,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.0017,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.017,
    Tlag = 10.200000000000001,
    Vdp = 0.0011,
    k12 = 7.194444444444445e-06,
    k21 = 7.194444444444445e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Moxifloxacin</td></tr><tr><td>ATC code:</td><td>J01MA14</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.28</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Moxifloxacin is a broad-spectrum fluoroquinolone antibiotic used to treat various bacterial infections, including respiratory tract infections, skin and soft tissue infections, and intra-abdominal infections. It is approved for use in many countries and commonly administered orally or intravenously.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult volunteers after single-dose oral administration.</p><h4>References</h4><ol><li><p>Greenberg, RG, et al., &amp; Walter, EB (2022). Population Pharmacokinetics of Moxifloxacin in Children. <i>Paediatric drugs</i> 24(2) 163–173. DOI:<a href=\"https://doi.org/10.1007/s40272-022-00493-3\">10.1007/s40272-022-00493-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35284983/\">https://pubmed.ncbi.nlm.nih.gov/35284983</a></p></li><li><p>Radtke, KK, et al., &amp; Garcia-Prats, AJ (2022). Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 74(8) 1372–1381. DOI:<a href=\"https://doi.org/10.1093/cid/ciab641\">10.1093/cid/ciab641</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34286843/\">https://pubmed.ncbi.nlm.nih.gov/34286843</a></p></li><li><p>Bock, M, et al., &amp; Moser, C (2023). Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 77(2) 242–251. DOI:<a href=\"https://doi.org/10.1093/cid/ciad168\">10.1093/cid/ciad168</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36947131/\">https://pubmed.ncbi.nlm.nih.gov/36947131</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01MA14 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Moxifloxacin;
